BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Partovi S, Coronado WM, Gadani S, Martin C, Thompson D, Levitin A, Kapoor B. Hepatic Encephalopathy After TIPS Placement: Predictive Factors, Prevention Strategies, and Management. Cardiovasc Intervent Radiol 2022. [PMID: 34981195 DOI: 10.1007/s00270-021-03045-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chang J, Höfer P, Böhling N, Lingohr P, Manekeller S, Kalff JC, Dohmen J, Kaczmarek DJ, Jansen C, Meyer C, Strassburg CP, Trebicka J, Praktiknjo M. Pre-operative TIPS may reduce post-operative ACLF occurrence. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100442] [Reference Citation Analysis]
3 Cannella R, Tselikas L, Douane F, Cauchy F, Rautou P, Duran R, Ronot M. Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100484] [Reference Citation Analysis]
4 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
5 Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, Xia D, Guo W, Wang Q, Li X, Yuan J, Cai H, Xia J, Yin Z, Fan D, Han G. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial. Hepatology 2022. [PMID: 35266571 DOI: 10.1002/hep.32453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
6 Wang HL, Lu WJ, Zhang YL, Nie CH, Zhou TY, Zhou GH, Zhu TY, Wang BQ, Chen SQ, Yu ZN, Jing L, Sun JH. Comparison of Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Cirrhosis With or Without Portal Vein Thrombosis: A Retrospective Study. Front Med (Lausanne) 2021;8:737984. [PMID: 34671621 DOI: 10.3389/fmed.2021.737984] [Reference Citation Analysis]
7 Meyer C, Paar Pérez AM, Chang J, Sprinkart AM, Böhling N, Luu AM, Kütting D, Jansen C, Luetkens J, Bischoff LM, Attenberger U, Strassburg CP, Trebicka J, Wolter K, Praktiknjo M. Cranial stent position is independently associated with the development of TIPS dysfunction. Sci Rep 2022;12:3559. [PMID: 35241785 DOI: 10.1038/s41598-022-07595-5] [Reference Citation Analysis]
8 Gairing SJ, Müller L, Kloeckner R, Galle PR, Labenz C. Review article: post-TIPSS hepatic encephalopathy-current knowledge and future perspectives. Aliment Pharmacol Ther 2022. [PMID: 35181894 DOI: 10.1111/apt.16825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mattock R, Tripathi D, O'Neill F, Craig J, Tanner J, Patch D, Aithal G. Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterol 2021;8:e000641. [PMID: 34429322 DOI: 10.1136/bmjgast-2021-000641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Praktiknjo M, Witt A, Schepis F, Garcia-Pagan JC, Merli M, Trebicka J. Reply to: "The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites". JHEP Rep 2021;3:100349. [PMID: 34505036 DOI: 10.1016/j.jhepr.2021.100349] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mansour S, Lemmers A, Trépo E, Moreno C, Deltenre P. The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites. JHEP Rep 2021;3:100319. [PMID: 34505034 DOI: 10.1016/j.jhepr.2021.100319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]